Cargando…

COL1A1: A potential therapeutic target for colorectal cancer expressing wild-type or mutant KRAS

Colorectal cancer (CRC) treatment primarily relies on chemotherapy along with surgery, radiotherapy and, more recently, targeted therapy at the late stages. However, chemotherapeutic drugs have high cytotoxicity, and the similarity between the effects of these drugs on cancerous and healthy cells li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zheying, Fang, Cheng, Wang, Yongxia, Zhang, Jinghang, Yu, Jian, Zhang, Yongxi, Wang, Xianwei, Zhong, Jiateng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192778/ https://www.ncbi.nlm.nih.gov/pubmed/30132520 http://dx.doi.org/10.3892/ijo.2018.4536

Ejemplares similares

COL1A1 promotes metastasis in colorectal cancer by regulating the WNT/PCP pathway
por: Zhang, Zheying, et al.
Publicado: (2018)

Association of MACC1 expression with lymphatic metastasis in colorectal cancer: A nested case-control study
por: Zhang, Zheying, et al.
Publicado: (2021)

Advances in the study of cancer metastasis and calcium signaling as potential therapeutic targets
por: Cui, Chaochu, et al.
Publicado: (2021)

Overexpression of Forkhead Box L1 (FOXL1) Inhibits the Proliferation and Invasion of Breast Cancer Cells
por: Zhong, Jiateng, et al.
Publicado: (2017)

FMR1 promotes the progression of colorectal cancer cell by stabilizing EGFR mRNA in an m(6)A-dependent manner
por: Hu, Yuhan, et al.
Publicado: (2022)

Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer
por: Knickelbein, Kyle, et al.
Publicado: (2014)

Study on the role of transcription factor SPI1 in the development of glioma
por: Du, Baoshun, et al.
Publicado: (2022)

Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients
por: Lin, Yu-Lin, et al.
Publicado: (2014)

Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients
por: Naseem, Madiha, et al.
Publicado: (2021)

Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients
por: Liu, Jungang, et al.
Publicado: (2021)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

MicroRNA-384 inhibits the progression of breast cancer by targeting ACVR1
por: Wang, Yongxia, et al.
Publicado: (2018)

LOX-1 Deletion Attenuates Myocardial Fibrosis in the Aged Mice, Particularly Those With Hypertension
por: Li, Xiao, et al.
Publicado: (2021)

Nestin expression involves invasiveness of esophageal carcinoma and its downregulation enhances paclitaxel sensitivity to esophageal carcinoma cell apoptosis
por: Zhang, Jinghang, et al.
Publicado: (2017)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer
por: Zhong, Longhui, et al.
Publicado: (2020)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
por: Ruan, Hang, et al.
Publicado: (2022)

Inhibition of lncRNA PART1 Chemosensitizes Wild Type but Not KRAS Mutant NSCLC Cells
por: Chen, Shu-Chen, et al.
Publicado: (2020)

Integrated multi-omics characterization of KRAS mutant colorectal cancer
por: Chong, Wei, et al.
Publicado: (2022)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

The Landscape of the Tumor-Infiltrating Immune Cell and Prognostic Nomogram in Colorectal Cancer
por: Zhong, Jiateng, et al.
Publicado: (2022)

MICA (∗)012:01 Allele Facilitates the Metastasis of KRAS-Mutant Colorectal Cancer
por: Ding, Weifeng, et al.
Publicado: (2020)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Wang, Jieqiong, et al.
Publicado: (2016)

Therapeutic Targets of KRAS in Colorectal Cancer
por: Rahman, Shafia, et al.
Publicado: (2021)

The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer
por: Diehl, J. Nathaniel, et al.
Publicado: (2021)

Targeting oxidative pentose phosphate pathway prevents recurrence in mutant Kras colorectal carcinomas
por: Gao, WenChao, et al.
Publicado: (2019)

A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS
por: Zhang, Xiang-Hua, et al.
Publicado: (2013)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer
por: Wong, Chi Chun, et al.
Publicado: (2022)

Yttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: Clinical and ccfDNA studies
por: Janowski, E., et al.
Publicado: (2017)

Mutant collagen COL11A1 enhances cancerous invasion
por: Lee, Carolyn S., et al.
Publicado: (2021)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer
por: Liu, Huashan, et al.
Publicado: (2021)

The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis
por: Zhong, Xi, et al.
Publicado: (2020)

High expression of COL10A1 is associated with poor prognosis in colorectal cancer
por: Huang, Haipeng, et al.
Publicado: (2018)

The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
por: Tria, Simon Manuel, et al.
Publicado: (2023)

Bromelain effectively suppresses Kras-mutant colorectal cancer by stimulating ferroptosis
por: Park, Sujeong, et al.
Publicado: (2018)

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
por: Kharbanda, Akriti, et al.
Publicado: (2014)

Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status
por: Zhang, Jun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mk2utrl6nqgln7bq8htkhggqg9